ETCTN LAO-MD017 10010: A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent, Persistent or Metastatic Cervical Cancer
Study of Drug in Patients with Recurrent, Persistent or Metastatic Cervical Cancer
Sponsor: NCI
Enrolling: Female Patients Only
IRB Number: AAAR4617
U.S. Govt. ID: NCT02921269
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu
Additional Study Information: A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent, Persistent or Metastatic Cervical Cancer. The purpose of this study is to test any good and bad effects of a combination of study drugs called atezolizumab and bevacizumab. The combination of atezolizumab and bevacizumab could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drugs will shrink the cancer by at least one quarter compared to its present size.
This study is closed
Investigator
Jason Wright, MD
Do You Qualify?
Have you been diagnosed with cervical cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Reena Vattakalam
rmv2110@cumc.columbia.edu
212-342-6895